Industrial valves produced by Velan Inc.
Picture of 911 Meso Info

911 Meso Info

911 Meso Info is a dedicated voice in the fight against mesothelioma, committed to raising awareness, providing reliable information, and empowering individuals affected by this rare disease. With a passion for advocacy, 911 Meso Info delivers insightful resources, up-to-date research, and practical tips to help patients and families navigate their mesothelioma journey. From treatment options and legal guidance to emotional support and prevention strategies, 911 Meso Info is your go-to source for comprehensive mesothelioma knowledge. Connect with us to stay informed and find strength in community. Follow 911 Meso Info for trusted advice and support, and join us in spreading awareness for a brighter tomorrow.

News Summary

Velan Inc. has divested its asbestos-related liabilities for approximately US$143 million, a move that will reduce financial risks and enhance growth.

Velan Inc. Makes Bold Move to Exclude Asbestos Liabilities

In a strategic maneuver that will reshape its financial landscape, Velan Inc. (TSE: VLN) has finalized a significant divestiture of its asbestos-related liabilities, transferring them to Global Risk Capital for a sum of approximately US$143 million. This decisive action is aimed at decreasing both operational and financial risks while enhancing the overall financial health of the company.

Unlocking Value Through Strategic Actions

The asbestos divestiture will see the complete removal of asbestos-related obligations from Velan’s balance sheet, effectively shielding the company from any future legacy liabilities associated with asbestos. Such a transformation is monumental, particularly for a company that has been dedicated to manufacturing high-quality industrial valves and establishing itself as a premier leader in valve solutions across various sectors.

This move was made possible through the sale of Velan’s subsidiaries in France to Framatome SAS, generating a total consideration of US$208.4 million, including the provision of an intercompany loan worth US$23.2 million. With this financial infusion, Velan not only fortifies its market position but importantly crowns its operational strategy aimed at sustainable profitable growth.

Maintaining U.S. Operations Amid Major Changes

Following the asbestos divestiture, Velan plans on retaining its U.S. operations under a newly birthed subsidiary, ensuring that its footprint in the clean energy sector, inclusive of nuclear applications, remains robust. Given that this sector is currently navigating a multi-year growth cycle, the company is well-poised to capture emerging opportunities and deliver superior performance.

With a market capitalization currently pegged at C$340 million and a year-to-date stock price performance marking an impressive 41.47%, Velan’s financial indicators are on an upward trajectory. The average trading volume has been stable, hovering around 33,147 shares, reflecting a continued investor interest.

Implications of the Divestiture

Despite the positive outlook, the asbestos divestiture is expected to trigger a one-time non-cash charge to earnings of around US$67 million before taxes. However, industry analysts believe that the proactive measures being undertaken will ultimately serve to unlock the inherent value within the company, positioning it for a sustained trajectory of profitable growth.

Furthermore, the divestiture comes alongside a comprehensive support framework, with Velan’s controlling shareholder entering into a voting and support agreement, signaling a unified approach to facilitating the France transaction. Financial advisory roles have been strategically allocated, with Ducera Partners LLC stepping in as the exclusive financial advisor for the Asbestos Divestiture, while BMO Capital Markets lends its expertise to the France transaction.

Fostering Continuous Growth

Founded in Montreal in 1950, Velan Inc. has carved out an enviable niche in the industrial sector, reporting sales of US$346.8 million during its last fiscal year. With a dedicated workforce comprising 1,617 employees and manufacturing operations spanning nine countries, the company is well-equipped to navigate the complexities of the current economic landscape.

In summary, Velan Inc.’s recent divestitures encapsulate a proactive strategy aimed at reducing liabilities and bolstering financial stability while allowing the firm to focus intently on its core mission—delivering high-quality valve solutions and driving sustainable growth in its chosen sectors. The road ahead is clearly paved for Velan, as it strategically orients itself toward a resilient and profitable future.

Deeper Dive: News & Info About This Topic

HERE Resources

Asbestos: A Silent Killer Claims Lives Across the UK
The Deadly Asbestos Legacy in Libby, Montana
South Africa’s Asbestos Legacy: A Battle with Mesothelioma
Serious Legal Consequences for Asbestos Abatement Violators in Massachusetts
Montana’s Court System on the Brink: New Legislation Targets Asbestos Claims
Legislative Action on Asbestos Compensation in Montana Stirs Up Controversy
Asbestos on the Decline: Major Shift in U.S. Policy as Chrysotile Faces Ban
Malignant Mesothelioma Market on the Rise: Growth Trends and Future Prospects
FDA Greenlights Pembrolizumab: A Beacon of Hope for Mesothelioma Patients
Johnson & Johnson’s Bankruptcy Proposal Faces Third Judicial Rejection

Additional Resources